Coherus Oncology Inc (CHRS)

Stock-Based Compensation

$21.54M

TTM · Period ending: · USD

CHRS logo

CHRS Stock-Based Compensation

Latest reported$21.54M
CHRS TTM Stock-Based Comp ($9.44M → $21.54M)
High-resolution chart · PNG

CHRS stock-based compensation history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Coherus Oncology Inc Stock-Based Compensation — Trailing twelve months (TTM) (USD)
Period endingStock-Based Compensation (USD)
21,535,000
21,988,000
24,975,000
20,566,000
24,045,000
18,624,000
20,571,000
24,985,000
28,070,000
38,147,000
43,110,000
44,038,000
46,367,000
50,140,000
50,737,000
39,011,000
38,668,000
36,413,000
40,418,000
50,291,000
47,659,000
45,489,000
28,605,000
26,004,000
25,530,000
24,097,000
33,591,000
35,146,000
34,873,000
35,571,000
34,797,000
36,970,000
36,593,000
36,975,000
36,065,000
32,750,000
32,837,000
29,913,000
27,421,000
24,910,000
21,384,000
19,857,000
16,721,000
15,373,000
13,364,000
9,953,000
11,062,000
7,547,000
5,810,000
11,847,000
9,438,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.